Skip to main content

Table 1 Sensitiser enhancement ratios (SER) for prostate cancer and prostate epithelial cells treated with citrate-AuNP or RALA-AuNP conjugates

From: Formulating RALA/Au nanocomplexes to enhance nanoparticle internalisation efficiency, sensitising prostate tumour models to radiation treatment

 

Mean SER

DEF @ 2 Gy

DEF @ 4 Gy

α

β

DU145

Radiation

–

–

–

0.15 ± 0.05

0.08 ± 0.007

Citrate-AuNP

0.9

0.9

0.85

− 0.06 ± 0.04

0.04 ± 0.01

RALA-AuNP

1.23

1.22

1.49

0.11 ± 0.07

0.03 ± 0.02

PC-3

Radiation

–

–

–

0.08 ± 0.07

0.032 ± 0.02

Citrate-AuNP

1.14

1.14

1.22

0.147 ± 0.05

0.028 ± 0.02

RALA-AuNP

1.54

1.66

2.04

0.35 ± 0.06

0.006 ± 0.02

PNT2-C2

Radiation

–

–

–

0.199 ± 0.04

0.04 ± 0.01

Citrate-AuNP

1.1

1.17

1.2

0.093 ± 0.091

0.028 ± 0.22

RALA-AuNP

0.96

0.97

1.07

− 0.045 ± 0.15

0.0053 ± 0.0039

  1. SER represents a ratio of the area under the curve for control verses treated cells using a survival fraction baseline of 0.1. DEF provides a ratio of survival fractions for control/AuNP treated at a single fixed dose point e.g., 2 Gy and 4 Gy, the survival fractions of which are extrapolated from the LQ survival curve. Similarly, α and β values have been extrapolated from LQ survival curves